高级检索
当前位置: 首页 > 详情页

MAP3K3 overexpression is associated with poor survival in ovarian carcinoma

文献详情

资源类型:
WOS体系:
Pubmed体系:

收录情况: ◇ SCIE

单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Ctr Canc,Huazhong 430000,Hubei,Peoples R China [2]Shihezi Univ, Sch Med, Dept Pathol, Xinjiang 832002, Peoples R China [3]Huazhong Univ Sci & Technol,Tongji Hosp,Tongji Med Coll,Dept Gynecol & Obstet,Huazhong 430000,Hubei,Peoples R China [4]Shihezi Univ, Sch Med, Affiliated Hosp 1, Dept Gynecol & Obstet, Xinjiang 832002, Peoples R China [5]Beijing ChaoYang Hosp, Dept Pathol, Beijing 100020, Peoples R China
出处:
ISSN:

关键词: Ovarian carcinoma MAP3K3 Prognosis Oncogene Biomarker

摘要:
Mitogen-activated protein kinase kinase kinase 3 (MAP3K3) is ubiquitously expressed in numerous tissues and is activated by various extracellular stimuli to regulate processes, such as cell proliferation and differentiation. Recent studies have identified potentially pathologic conditions of MAP3K3 as an oncogene that promotes tumor progression and metastasis in a number of malignancies. However, the clinical significance of MAP3K3 expression in ovarian carcinoma (OC) remains unclear. In this study, the correlation between MAP3K3 expression and OC prognosis was assessed by immunohistochemistry. MAP3K3 overexpression was observed in 59.1% (55/93) of OCs and was significantly associated with histological type and grade, chemotherapy response, and challenge model (P < .05, respectively). MAP3K3 overexpression was also used as an independent prognostic marker for decreased disease-free survival and overall survival. In OC cell lines, MAP3K3 expression was evaluated by Westem blot analysis, quantitative real-time polymerase chain reaction, and immunofluorescence. High MAP3K3 expression is significantly detected in SKOV3, C13*, and A2780 cells. All these findings suggested that MAP3K3 overexpression is an independent poor prognostic indicator of OC and can be a clinically effective biomarker of OC. (C) 2015 Elsevier Inc. All rights reserved.

基金:
语种:
被引次数:
WOS:
PubmedID:
中科院(CAS)分区:
出版当年[2015]版:
大类 | 3 区 医学
小类 | 3 区 病理学
最新[2025]版:
大类 | 3 区 医学
小类 | 2 区 病理学
JCR分区:
出版当年[2014]版:
Q2 PATHOLOGY
最新[2023]版:
Q2 PATHOLOGY

影响因子: 最新[2023版] 最新五年平均 出版当年[2014版] 出版当年五年平均 出版前一年[2013版] 出版后一年[2015版]

第一作者:
第一作者单位: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Ctr Canc,Huazhong 430000,Hubei,Peoples R China [2]Shihezi Univ, Sch Med, Dept Pathol, Xinjiang 832002, Peoples R China
通讯作者:
通讯机构: [1]Huazhong Univ Sci & Technol,Tongji Med Coll,Tongji Hosp,Ctr Canc,Huazhong 430000,Hubei,Peoples R China [2]Shihezi Univ, Sch Med, Dept Pathol, Xinjiang 832002, Peoples R China [5]Beijing ChaoYang Hosp, Dept Pathol, Beijing 100020, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:434 今日访问量:0 总访问量:419 更新日期:2025-05-01 建议使用谷歌、火狐浏览器 常见问题

版权所有:重庆聚合科技有限公司 渝ICP备12007440号-3 地址:重庆市两江新区泰山大道西段8号坤恩国际商务中心16层(401121)